Table 1.
Summary of characteristics of 27 trials included in the review
| Characteristics | Freq. (%) | |
| Total | 31 (100) | |
| Country | UK | 6 (19.4%) |
| Sweden | 5 (16.1%) | |
| Netherlands | 4 (12.9%) | |
| USA | 4 (12.9%) | |
| Europe | 7 (22.6%) | |
| Others | 5 (16.1%) | |
| Participants (n) | Median (IQR) | 419 (224–883) |
| Gender | Male only | 1 (3.2) |
| Female only | 1 (3.2) | |
| Both | 29 (93.5) | |
| Age | Minimum age, median (IQR) | 30 (20–40) |
| Maximum age, median (IQR) | 65 (60–74) | |
| Intervention outcomes | CVD risk | 14 (45.2) |
| Body weight | 25 (80.6) | |
| Blood pressure | 26 (83.9) | |
| Serum cholesterol | 26 (83.9) | |
| Diet | 18 (58.1) | |
| Physical activity | 21 (67.7) | |
| Alcohol | 6 (19.4) | |
| Smoking | 15 (48.4) | |
| Targeted behaviours (n) | Two behaviours | 11 (35.5) |
| Three behaviours | 12 (38.7) | |
| Four behaviours | 7 (22.6) | |
| Five behaviours | 1 (3.2) | |
| Follow-up duration | 12 months | 18 (58.1) |
| >12 months | 13 (41.9) | |
Figures are frequencies (column percent).
CVD, cardiovascular disease.